Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pergolide mesylate
Drug ID BADD_D01736
Description Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
Indications and Usage Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.
Marketing Status Discontinued
ATC Code N04BC02
DrugBank ID DB01186
KEGG ID D00502
MeSH ID D010479
PubChem ID 47812
TTD Drug ID D04JCN
NDC Product Code 47848-008
Synonyms Pergolide | Pharken | Permax | Celance | Parkotil | LY-127809 | LY127809 | LY-127,809 | LY127,809 | Pergolide Mesylate | Mesylate, Pergolide
Chemical Information
Molecular Formula C20H30N2O3S2
CAS Registry Number 66104-23-2
SMILES CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seborrhoea23.02.07.001--Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Shock24.06.02.002--Not Available
Sialoadenitis07.06.04.002; 11.01.04.002--
Sinusitis11.01.13.005; 22.07.03.007--
Skin cancer23.08.02.002; 16.03.02.002--Not Available
Skin discolouration23.03.03.005--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Splenomegaly01.09.02.001--Not Available
Stupor19.02.05.004; 17.02.04.007--Not Available
Surgery25.01.02.003--Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachycardia02.03.02.007--Not Available
Tenosynovitis15.07.01.004--Not Available
Thinking abnormal17.02.05.023; 19.10.03.001--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thyroid adenoma16.37.01.001; 05.02.05.003--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tooth abscess11.01.04.003; 07.09.01.003--Not Available
Torticollis17.01.03.003; 15.05.04.003--Not Available
Tremor17.01.06.002--
Urethral pain20.02.02.014--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages